PCIA
AGIO icon

Prime Capital Investment Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Prime Capital Investment Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40
Closed -$3K – 257
2018
Q2 		$3K Buy
+40
New +$3.49K ﹤0.01% 307

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Prime Capital Investment Advisors's AGIO Position: Q3 2018 in Review

Prime Capital Investment Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2018, closing a stake of 40 shares — an estimated $3K sold.

Prime Capital Investment Advisors first reported a position in AGIO in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2018.

  • Prime Capital Investment Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 40 Agios Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Prime Capital Investment Advisors first reported a position in Agios Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Prime Capital Investment Advisors's Agios Pharmaceuticals position peaked at $3K in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2018.

Based on Prime Capital Investment Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.